"When our leaders talk about integration, what do they really mean? It's hypocrisy when they tell us to use outpatient [clinics], when they know mobile clinics exist because of their criminalisation ...

“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th ...

Artifical intelligence (AI) featured prominently at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda last week. Experts expressed excitement – and some ...

A high-level panel discussion convened at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda drew together representatives from global funding foundations, ...

More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed ...

Garnering a standing ovation at IAS 2025, Sameer Sah, from Medical Aid for Palestinians, provided a devastating first-hand account of what’s been happening for nearly two years in Gazan healthcare ...

Monthly oral PrEP pill advances to phase III trials Professor Kenneth Mayer at IAS 2025. ©Jacques Nkinzingabo/IAS. CC BY-SA 4.0. A once-monthly oral HIV prevention pill has shown promising results in ...

An investigational once-monthly pill holds promise for HIV pre-exposure prophylaxis (PrEP), according to mid-stage study results presented yesterday at the 13th International AIDS Society Conference ...

Intermittent HIV treatment schedules – such as weekends off treatment – may not be inferior to continuous treatment in adults with well-controlled HIV, but they are not suitable for adolescents with ...

Injectable treatment with long-acting cabotegravir and rilpivirine is as effective as dolutegravir-based oral treatment in adults with HIV in sub-Saharan Africa who have a history of treatment ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda has been dominated by the impact of the US government funding cuts. Especially urgent are discussions on ...

A randomised trial presented on Tuesday at the 13th International AIDS Society Conference on HIV Science (IAS 2025) showed that switching from medications thought to cause weight gain did ...